A five-year bull run in biotech has made scientists into millionaires, booked bonuses for bankers, and put venture capitalists into increasingly fancy cars. But in an industry prone to booms and busts, insiders with long memories aren’t getting too comfortable.

“I’m seeing a lot of investors making a lot of assumptions that may be accurate, but these assumptions are now becoming the consensus, and if anything goes wrong, there’s a long way down,” said Josh Schimmer, a biotech analyst at Evercore ISI.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

    • There have been ridiculous run ups for and valuations for companies like BGNE, ATRA, NKTR and countless others that are no where near approved/marketable products. In earlier times, this would have been considered a bubble.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy